Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
Autor: | Arribas, José R1 joser.arribas@salud.madrid.org, Girard, Pierre-Marie2, Landman, Roland3, Pich, Judit4, Mallolas, Josep4, Martínez-Rebollar, María4, Zamora, Francisco X1, Estrada, Vicente5, Crespo, Manuel6, Podzamczer, Daniel7, Portilla, Joaquín8, Dronda, Fernando9, Iribarren, José A10, Domingo, Pere11, Pulido, Federico12, Montero, Marta13, Knobel, Hernando14, Cabié, André15, Weiss, Laurence16, Gatell, José M4 |
---|---|
Zdroj: | Lancet Infectious Diseases. Jul2015, Vol. 15 Issue 7, p785-792. 8p. |
Databáze: | Academic Search Ultimate |
Externí odkaz: |